Abstract
Non-invasive prenatal testing (NIPT) for common fetal aneuploidies using circulating cell free DNA in maternal plasma has been widely adopted in clinical practice for its sensitivity and accuracy. However, the detection of subchromosomal abnormalities or monogenetic variations using such a method showed no cost-effectiveness or satisfactory accuracy. Here we show that with the aid of polymorphic sites sequencing, fetal fraction of the sample and genotype of the target site were determined with high accuracy. Then genetic variations at the chromosomal, subchromosomal and nucleotide levels were detected using the overall allelic goodness-of-fit test of all target polymorphic sites to each possible genetic model. Finally, relative allelic distributions for each amplicon were visualized and genetic variations at the chromosomal, subchromosomal and nucleotide levels were determined by distinct characteristic clusters on allelic distribution plot of each possible genetic model. As no parental genetic information was required and all allelic information retained for amplicon sequencing, the reported approach has the potential to simultaneously detect genetic variations at different levels, facilitating the extension of NIPT to all common genetic conditions for general low-risk pregnancies and target variations for certain high-risk pregnancy groups.
Competing Interest Statement
A patent application has been filed relating to this work.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were retrieved from NIH sra database and only computation was done on the data. Therefore, we regard that it was exempted naturally.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos